中华眼底病杂志

中华眼底病杂志

地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性:随机、假注射对照、多中心研究

查看全文

目的 评估地塞米松玻璃体腔植入物(DEX)治疗中国患者视网膜静脉阻塞继发黄斑水肿(RVO-ME)的安全性和有效性。 方法 为期6个月的随机、双盲、假注射对照、多中心、3期临床研究,此后接续为期2个月的开放标签的延展研究。视网膜分支(BRVO)或中央静脉阻塞(CRVO)患眼于基线时接受DEX植入(n=129)或假注射(n=130)治疗;治疗后6个月时,两组中满足再治疗标准的全部患眼均再次接受DEX植入治疗。有效性变量包括最佳矫正视力(BCVA)和黄斑中心凹视网膜厚度(CRT)。BCVA检查采用早期治疗糖尿病视网膜病变研究组视力表进行。光相干断层扫描(OCT)检查采用德国Heidelberg公司Spectralis OCT仪或德国Zeiss公司Cirrus OCT仪进行。 结果 治疗后6个月中(主要终点),DEX治疗组BCVA较基线提高≥15个字母的时间早于假注射组(P<0.001)。治疗后第2个月时(效应峰值),DEX治疗组、假注射组BCVA较基线提高≥15个字母患者百分比分别为34.9%,11.5%。DEX治疗组、假注射组平均BCVA较基线分别提高(10.6±10.4)、(1.7±12.3)个字母;平均CRT分别较基线下降(407±212)、(62±224) μm(P<0.001)。DEX治疗组CRVO、BRVO患眼治疗效果均优于假注射组。主要常见治疗相关不良事件为眼压升高,均可通过局部降眼压药物控制;无患者需要接受抗青光眼手术。 结论 DEX治疗中国患者RVO-ME具有良好的安全性和显著的临床疗效;单次植入DEX较假注射可获得持续3~4个月的视力和解剖结构改善。

Objective To evaluate the safety and efficacy of dexamethasone intravitreal implant 0.7 mg (DEX) for treatment of macular edema associated with retinal vein occlusion (RVO). Methods This study was a six-month, randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial with a 2-month open-label study extension. Patients with branch or central RVO received DEX (n=129) or sham procedure (n=130) in the study eye at baseline; all patients who met re-treatment criteria received DEX at month 6. Efficacy measures included Early Treatment Diabetic Retinopathy Study (ETDRS), best-corrected visual acuity (BCVA), and central retinal thickness (CRT) on optical coherence tomography. Results Time to ≥15-letter BCVA improvement from baseline during the first 6 months (primary endpoint) was earlier with DEX than sham (P<0.001). At month 2 (peak effect), the percentage of patients with ≥15-letter BCVA improvement from baseline was DEX: 34.9%, sham: 11.5%; mean BCVA change from baseline was DEX: 10.6±10.4 letters, sham: 1.7±12.3 letters; and mean CRT change from baseline was DEX: −407±212 μm, sham: −62±224 μm (all P<0.001). Outcomes were better with DEX than sham in both branch and central RVO. The most common treatment-emergent adverse event was in-creased intraocular pressure (IOP). Increase sin IOP generally were controlled with topical medication. Mean IOP normalized by month 4, and no patient required incisional glaucoma surgery. Conclusions DEX had a favorable safety profile and provided clinically significant benefit in a Chinese patient population with RVO. Visual and anatomic outcomes were improved with DEX relative to sham for 3 - 4 months after a single implant.

关键词: 肾上腺皮质激素类; 药物释放系统; 玻璃体内注射; 黄斑水肿; 视网膜静脉闭塞; 随机对照试验

Key words: Corticosteroids; Drug delivery systems; Intravitreal injections; Macular edema; Retinal vein occlusion; Randomized controlled trial

引用本文: 黎晓新, 王宁利, 梁小玲, 徐格致, Xiao-yanLi, JennyJiao, JeanLou, YehiaHashad, 中国视网膜静脉阻塞地塞米松玻璃体腔植入剂研究组. 地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性:随机、假注射对照、多中心研究. 中华眼底病杂志, 2018, 34(3): 212-220. doi: 10.3760/cma.j.issn.1005-1015.2018.03.003 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Jonas JB, Xu L, Wang YX. The Beijing eye study[J]. Acta Ophthalmol, 2009, 87(3):247-261. DOI: 10.1111/j.1755-3768.2008.01385.x.
2. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management[J].J Thromb Haemost, 2010, 8(9):1886-1894. DOI: 10.1111/j.1538-7836.2010.03909.x.
3. Fujihara-Mino A, Mitamura Y, Inomoto N, et al. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion[J]. Clin Ophthalmol, 2016, 10:1305-1313. DOI: 10.2147/OPTH.S110793.
4. Deobhakta A, Chang LK. Inflammation in retinal vein occlusion[J/OL]. Int J Inflam, 2013, 2013:438412[2013-04-03]. https://dx.doi.org/10.1155/2013/438412. DOI: 10.1155/2013/438412.
5. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases[J].Acta Ophthalmol Scand, 2005, 83(6):645-663. DOI: 10.1111/j.1600-0420.2005.00592.x.
6. Haller JA, Bandello F, Belfort R Jr, et al, Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118(12):2453-2460. DOI: 10.1016/j.ophtha.2011.05.014.
7. Robinson MR, Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant[J]. Expert Rev Clin Pharmacol, 2012, 5(6):629-647. DOI: 10.1586/ecp.12.55.
8. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema[J].Retina,2009, 29(1):46-51. DOI: 10.1097/IAE.0b013e318188c814.
9. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant[J]. Invest Ophthalmol Vis Sci, 2011, 52(1):80-86. DOI: 10.1167/iovs.10-5285.
10. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion[J]. Ophthalmology, 2010, 117(6):1134-1146. DOI: 10.1016/j.ophtha.2010.03.032.
11. Kuppermann BD, Haller JA, Bandello F, et al. Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion[J]. Retina, 2014, 34(9):1743-1749. DOI: 10.1097/IAE.0000000000000167.
12. Cheng JW, Cheng SW, Ma XY, et al. The prevalence of primary glaucoma in main land China: asystematic review and meta-analysis[J]. J Glaucoma, 2013, 22(4):301-306. DOI: 10.1097/IJG.0b013e31824083ca.
13. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1[J]. Arch Ophthalmol, 1985, 103(12):1796-1806.
14. Chew EY, Kim J, Sperduto RD, et al. Evaluation of the age-related eye disease study clinical lens grading system. AREDS report no. 31[J].Ophthalmology, 2010, 117(11):2112-2119. DOI: 10.1016/j.ophtha.2010.02.033.
15. Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant[J]. Ophthalmology, 2012, 119(6):1190-1198. DOI: 10.1016/j.ophtha.2011.12.028.
16. Jaissle GB, Szurman P, Feltgen N, et al; Retinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion[J]. Graefe’s Arch Clin Exp Ophthalmol, 2011, 249(2): 183-192. DOI: 10.1007/s00417-010-1470-2.
17. Larsen M, Waldstein SM, Boscia F, et al; CRYSTAL Study Group. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study[J]. Ophthalmology, 2016, 123(5):1101-1111. DOI: 10.1016/j.ophtha.2016.01.011.
18. Augustin AJ, Holz FG, Haritoglou C, et al. Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion[J]. Ophthalmologica, 2015, 233(1):18-26. DOI: 10.1159/000368840.
19. Singer MA, Capone A Jr, Dugel PU, et al; SHASTA Study Group. Two or more dexamethasone intravitreal implants as mono therapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study[J]. BMC Ophthalmol, 2015, 15:33. DOI: 10.1186/s12886-015-0018-y.
20. Querques L, Querques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion[J]. Ophthalmologica, 2013, 229(1):21-25. DOI: 10.1159/000342160.
21. Eter N, Mohr A, Wachtlin J, et al; German Ozurdex in RVO Real World Study Group. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial[J]. Graefe’s Arch Clin ExpOphthalmol, 2016, 255(1):77-87. DOI: 10.1007/s00417-016-3431-x.
22. Maturi RK, Pollack A, Uy HS, et al; Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study[J]. Retina, 2016, 36(6):1143-1152. DOI: 10.1097/IAE.0000000000001004.
23. Reid GA, Sahota DS, Sarhan M. Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds[J].Retina, 2015, 35(8):1647-1655. DOI: 10.1097/IAE.0000000000000524.